Meta-epidemiological study of 385 two-arm phase 3 oncology RCTs: 104 of 244 evaluable trials (43%) had control arm overperformance, more often with overall survival as primary end point (56% vs 33%); better-than-expected controls were linked to failing the primary end point.
Meta-analysisn = 385 trials
Nalin et al. Control arm overperformance in phase 3 oncology clinical trials